Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19

Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARSCoV-2): Facts and myths

(2020) Chih-Cheng Lai et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome

(2020) Toshio Hirano et al.   IMMUNITY

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

(2020) Yang Cao et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Cytokine release syndrome in severe COVID-19

(2020) John B. Moore et al.   SCIENCE

Immunomodulatory Drugs in the Management of SARS-CoV-2

(2020) Daniel R. Burrage et al.   Frontiers in Immunology

The regulation of JAKs in cytokine signaling and its breakdown in disease

(2018) Henrik M. Hammarén et al.   CYTOKINE

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

(2012) Apostolos Kontzias et al.   CURRENT OPINION IN PHARMACOLOGY